[1]. Marbury T, Huang WC, Strange P, Lebovitz H et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Research and Clinical Practice .1999, 43(3):155-166. [2]. David R. Owens . Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs . Diabetic Medicine 1998,15 : S28-S36. [3]. J Fuhlendorff, P Rorsman, H Kofod. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998. 47 (3): 345-351 . [4]. R Moses, R Slobodniuk, S Boyages. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care . 22 (1 ) : 119-124 . [5]. Julio Rosenstock, MD, David R. Hassman, DO, Robert D. Madder, DO. Diabetes Care June 2004 vol. 27 no. 6 1265-1270 [6]. Shiling Hu1, Shuya Wang1, Barbara Fanelli1. Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide . JPET , 2000,293 (2 ): 444-452 . |